Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
Seventy-six dogs with clinical acquired atrioventricular valvular disease were evaluated to determine the efficacy of pimobendan (n=41) versus benazepril hydrochloride (n=35) in a randomized, positive-controlled, multicenter study. The study was divided into 56-day and long-term evaluation periods. In a subgroup of dogs with concurrent furosemide treatment (pimobendan [n=31], benazepril [n=25]), the Heart Insufficiency Score improved in favor of pimobendan (P=0.0011), equating to a superior overall efficacy rating (P<0.0001) at day 56. Long-term median survival (i.e., death or treatment failure) for dogs receiving pimobendan was 415 days versus 128 days for dogs not on pimobendan (P=0.0022).
Lombard
Christophe W
CW
Klinik für kleine Haustiere, Universität Bern, Bern, Switzerland.
Jöns
Olaf
O
Bussadori
Claudio M
CM
D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D005260:Female; D006349:Heart Valve Diseases / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008297:Male; D011724:Pyridazines / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D001552:Benzazepines; D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan; C044946:benazepril